問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

Recruiting Trial

1,298Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

3103Cases

2018-07-02 - 2021-06-08

Phase II

A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer

  • Condition/Disease

    Advanced Triple-negative Breast Cancer

  • Test Drug

    LAG525、PDR001

Participate Sites
3Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

2020-10-01 - 2022-10-24

Phase II

A partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody, CFZ533, in de novo and maintenance kidney transplant recipients (CIRRUS I)

  • Condition/Disease

    kidney transplantion

  • Test Drug

    CFZ533

Participate Sites
3Sites

Not yet recruiting3Sites

2020-05-01 - 2023-05-31

Phase III

A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301

  • Condition/Disease

    Chronic Spontaneous Urticaria

  • Test Drug

    QGE031

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2021-05-31 - 2023-03-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2006-01-01 - 2008-01-01

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Study ended3Sites

2023-08-11 - 2023-10-18

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-10-30 - 2022-10-18

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-10-24 - 2024-03-31

Phase III

SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

  • Condition/Disease

    Obesity

  • Test Drug

    Semaglutide B 3.0 mg/mL PDS290 or Semaglutide placebo

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2019-08-20 - 2022-03-01

Phase III

PIONEER 12 Multi-regional clinical trial: Efficacy and safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes mellitus treated with metformin

  • Condition/Disease

    Diabetes Mellitus, Type 2

  • Test Drug

    Semaglutide Tablets

Participate Sites
4Sites

Terminated4Sites

2019-08-01 - 2022-03-31

Phase III

PIONEER 11 Multi-regional clinical trial: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only

  • Condition/Disease

    type 2 diabetes mellitus

  • Test Drug

    Semaglutide Tablets

Participate Sites
3Sites

Terminated3Sites

1 283 284 285 286 287 311
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB